HIMS vs PFE

Hims & Hers retains growth potential driven by its D2C telehealth platform and positioning in chronic care like GLP-1s, evidenced by 59% YoY FY25 revenue growth and 2.5 million subscribers. However, the investment thesis for 10x growth within 3-5 years has significantly weakened since the last analysis. Intensified regulatory pressure on compounded GLP-1s directly threatens its fastest-growing seg...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...